The U.S. Food and Drug Administration on Friday agreed to reconsider its recent decision barring drug compounders from ...
Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...
The drug combines semaglutide, the active ingredient in Wegovy, with another compound that mimics a metabolic hormone called amylin. Cagrisema’s Phase 3 trial, called REDEFINE1, is due to wrap up and ...